Annovis Bio Inc. (NYSE: ANVS) has announced a strategic collaboration with Weave Bio to support preparation of its planned New Drug Application (NDA) for buntanetap, an investigational oral therapy targeting neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The partnership aims to leverage artificial intelligence to draft, review, and manage NDA documents, potentially accelerating the regulatory submission process for a drug that addresses significant unmet needs in neurology.
Under the collaboration, Annovis will deploy the Weave AI platform to handle the substantial documentation required for an NDA. However, the company emphasized that its regulatory and clinical teams will retain full responsibility for content, verification, and final approval of all documents submitted to the U.S. Food and Drug Administration (FDA). This hybrid approach seeks to combine the efficiency of AI with the rigor of human oversight, a critical consideration for regulatory submissions where accuracy and compliance are paramount.
The timing of this collaboration aligns with a key milestone: Annovis recently completed enrollment in its pivotal Phase 3 study of buntanetap for Alzheimer's disease. The trial enrolled 862 biomarker-confirmed patients, surpassing the original target of 760. The company is now focused on achieving database lock for the six-month treatment period in December 2026, with top-line symptomatic data expected in March 2027. By preparing most of the NDA before the data readout, Annovis aims to expedite the submission process if the results are positive.
Buntanetap, formerly posiphen, is a once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis hopes to halt disease progression and improve cognitive and motor functions. This mechanism differentiates buntanetap from other therapies that primarily target symptoms or single proteins.
For patients and caregivers, this collaboration signals a potential acceleration in bringing a novel treatment option to market. Alzheimer's and Parkinson's diseases affect millions worldwide, and current therapies offer limited disease-modifying effects. A successful NDA would represent a significant advancement. For the biotech industry, the move highlights the growing adoption of AI in regulatory affairs, which could reduce costs and timelines for drug development. Investors may view this as a positive step toward commercialization, though risks remain until clinical data are available.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage company dedicated to neurodegenerative diseases. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest updates on ANVS are available at https://ibn.fm/ANVS. For the full press release, visit https://ibn.fm/FMiEX. This news is distributed by BioMedWire, a specialized communications platform for the biotech and life sciences sectors, part of the Dynamic Brand Portfolio at IBN.
